- Home
- LCFY vs BCLI Comparison
LCFY vs BCLI Comparison
Compare LCFY & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCFY
- BCLI
- Stock Information
- Founded
- LCFY 2009
- BCLI 2000
- Country
- LCFY Australia
- BCLI United States
- Employees
- LCFY N/A
- BCLI N/A
- Industry
- LCFY
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LCFY
- BCLI Health Care
- Exchange
- LCFY Nasdaq
- BCLI Nasdaq
- Market Cap
- LCFY 7.0M
- BCLI 7.9M
- IPO Year
- LCFY 2022
- BCLI N/A
- Fundamental
- Price
- LCFY $4.39
- BCLI $1.32
- Analyst Decision
- LCFY
- BCLI Strong Buy
- Analyst Count
- LCFY 0
- BCLI 1
- Target Price
- LCFY N/A
- BCLI $30.00
- AVG Volume (30 Days)
- LCFY 39.5K
- BCLI 145.7K
- Earning Date
- LCFY 05-27-2025
- BCLI 05-15-2025
- Dividend Yield
- LCFY N/A
- BCLI N/A
- EPS Growth
- LCFY N/A
- BCLI N/A
- EPS
- LCFY N/A
- BCLI N/A
- Revenue
- LCFY $2,668,385.00
- BCLI N/A
- Revenue This Year
- LCFY N/A
- BCLI N/A
- Revenue Next Year
- LCFY N/A
- BCLI N/A
- P/E Ratio
- LCFY N/A
- BCLI N/A
- Revenue Growth
- LCFY N/A
- BCLI N/A
- 52 Week Low
- LCFY $2.20
- BCLI $0.72
- 52 Week High
- LCFY $11.23
- BCLI $10.05
- Technical
- Relative Strength Index (RSI)
- LCFY 46.92
- BCLI 59.70
- Support Level
- LCFY $4.20
- BCLI $1.10
- Resistance Level
- LCFY $5.38
- BCLI $1.26
- Average True Range (ATR)
- LCFY 0.60
- BCLI 0.14
- MACD
- LCFY 0.02
- BCLI 0.02
- Stochastic Oscillator
- LCFY 18.69
- BCLI 75.00
About LCFY Locafy Limited
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.